All News
The National Prevalence of HLA-B27 in the U.S.
HLA-B27 is found 6.1% of the US population, but with is seen in >90% patients with ankylosing spondylitis. HLA-B27 increases risk of spondylitis, uveitis and heart block. [Image credit: "HLA-B*2705" by Pdeitiker - Own work. Licensed under Public Domain via Wikimedia Commons]
Read Article
Patient perspectives in the management of psoriasis and PsA
A psoriasis population survey finds psoriasis or psoriatic arthritis in 1.4%-3.3% of North American and European households. Many (27-53%) rated their disease as “severe”.
Read Article
AS vs. SpA Responses with Combination Treatment
Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.
Read Article
The Prevalence of Ankylosing Spondylitis
A retrospective study of the national register in Sweden identified a total of 11,030 cases with an ankylosing spondylitis (AS) diagnosis (as of 2009) were identified in the National Patient Register, giving a point prevalence of 0.18% in 2009. Men had a higher prevalence of ankylo
Read Article
Psoriatic Arthritis Has a New FDA Approved DMARD - Apremilast
In March 2014 the FDA approved apremilast (Otezla) for use in psoriatic arthritis based on three large"Palace" trials involving 1493 psoriatic arthritis patients. This ACR Hotline reviews the drugs use, efficacy, and toxicity.
Read Article
